2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market

[NewsFeeder]

Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year.

Continue reading...